Peak Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Peak Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,720	Closed	-$223K	–	148
2022 Q4	$223K	Buy	+1,720	New	+$199K	0.06%	130
2021 Q1	–	Sell	-1,420	Closed	-$242K	–	157
2020 Q4	$242K	Buy	+1,420	New	+$210K	0.06%	130
2020 Q2	–	Sell	-2,825	Closed	-$276K	–	132
2020 Q1	$276K	Buy	+2,825	New	+$323K	0.11%	88

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Peak Asset Management's SRPT Position: Q1 2023 in Review

Peak Asset Management sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 1,720 shares — an estimated $223K sold.

Peak Asset Management first reported a position in SRPT in Q1 2020 and held it in 3 quarters. The position peaked at $276K in Q1 2020. 426 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

Peak Asset Management reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
Peak Asset Management sold 1,720 Sarepta Therapeutics shares in Q1 2023, an estimated $223K.
Peak Asset Management first reported a position in Sarepta Therapeutics in Q1 2020 and held it in 3 quarters.
Peak Asset Management's Sarepta Therapeutics position peaked at $276K in Q1 2020.
426 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on Peak Asset Management's 13F filing for Q1 2023, filed 11 May 2023.